editorial ries around the world. Molecules are being manipulated and moulded to create compounds with increasingly selective effects on central nervous system neurotransmitters in the hope of developing more effective treatments with fewer untoward side-effects.
The search for new and more effective psychotropic drugs has also been accelerated in the last few decades by the recognition that psychiatric disorders are very prevalent, and that a much broader spectrum of these disorders than previously recognised can benefit from medication.
Drug development
A drug development programme is an extremely complex process, comprising many phases over a number of years. In the Considerable reduction in depression scores was recorded in the hypericum group, and if this had been an uncontrolled study, the investigators might well have concluded that hypericum was an effective antidepressant. But the placebo group displayed a similar reduction in depressive symptomatology -i.e. hypericum was no better than placebo. However, the sertraline group also did not differ significantly from either placebo or hypericum. This, then, was a 'failed study'. 
Conclusion
There are some aspects of clinical trials as currently conducted that raise legitimate concerns among researchers. The policy of accelerating drug development programmes in order to extend the period of patent protection should be revisited. The resultant editorial pressure to recruit subjects as rapidly as possible is probably a major factor in the increased placebo response rates, as unsuitable subjects are more likely to be included. However, provided that individual clinicians make every effort to conduct trials both meticulously and ethically, clinical trials enhance the quality of care available to patients who might otherwise not have access to newer therapies. Based on currently available information, the RCT remains the best method of proving the efficacy and safety of newly developed drugs, and a placebo arm is a necessary evil until the advent of a better alternative. In the meantime, it is incumbent upon researchers to attempt to improve the RCT design rather than reject it.
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